Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.